Profit Or Loss [Abstract]

Innate Pharma - Filing #2811003

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Profit or loss [abstract]
Profit (loss) [abstract]
Revenue	—	61 641 EUR	—	—	—	—	—	—	—	—	57 674 EUR	—	—	—	—	—
Profit (loss) from operating activities	—	12 669 EUR	—	—	—	—	—	—	—	—	57 425 EUR	—	—	—	—	—
Finance income	—	6 934 EUR	—	—	—	—	—	—	—	—	4 775 EUR	—	—	—	—	—
Finance costs	—	1 835 EUR	—	—	—	—	—	—	—	—	5 321 EUR	—	—	—	—	—
Profit (loss) before tax	—	7 570 EUR	—	—	—	—	—	—	—	—	57 972 EUR	—	—	—	—	—
Tax expense (income)	—	— EUR	—	—	—	—	—	—	—	—	— EUR	—	—	—	—	—
Profit (loss) from continuing operations	—	7 570 EUR	—	—	—	—	—	—	—	—	57 972 EUR	—	—	—	—	—
Profit (loss) from discontinued operations	—	— EUR	—	—	—	—	—	—	—	—	131,000 EUR	—	—	—	—	—
Profit (loss)	— EUR	7 570 EUR	— EUR	7 570 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	58 103 EUR	— EUR	— EUR	58 103 EUR	— EUR	— EUR
Earnings per share [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Earnings per share [abstract]
Earnings per share [line items]
Basic earnings per share [abstract]
Basic earnings (loss) per share from continuing operations	—	9.00	—	—	—	—	—	—	—	—	73.00	—	—	—	—	—
Basic earnings (loss) per share from discontinued operations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Basic earnings (loss) per share	—	9.00	—	—	—	—	—	—	—	—	73.00	—	—	—	—	—
Diluted earnings per share [abstract]
Diluted earnings (loss) per share from continuing operations	—	9.00	—	—	—	—	—	—	—	—	73.00	—	—	—	—	—
Diluted earnings (loss) per share from discontinued operations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diluted earnings (loss) per share	—	9.00	—	—	—	—	—	—	—	—	73.00	—	—	—	—	—